{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:02:37Z","timestamp":1789754557191,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.radonc.2026.111476","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:48:54Z","timestamp":1773272934000},"page":"111476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cumulative dose analysis following elective pelvis re-irradiation at junction with primary prostate radiotherapy from the OLIGOPELVIS GETUG P07 trial"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-0693","authenticated-orcid":false,"given":"Lo\u00efg","family":"Vaugier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chiavassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Ayadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Blanc-Lapierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Delpon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111476_b0005","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctro.2024.100871","article-title":"Reirradiation \u2212 still navigating uncharted waters?","volume":"49","author":"Andratschke","year":"2024","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.radonc.2026.111476_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V\u2013STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2024.02.013","article-title":"Long-term Outcomes and patterns of Relapse following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07)","volume":"87","author":"Vaugier","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111476_b0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a Multicenter phase II Trial of combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111476_b0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1186\/s12885-015-1579-0","article-title":"OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer","volume":"15","author":"Supiot","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111476_b0040","doi-asserted-by":"crossref","unstructured":"S. K. Yi et al., \u201cDevelopment of a Standardized Method for Contouring the Lumbosacral Plexus: A Preliminary Dosimetric Analysis of this Organ at Risk Among 15 Patients Treated With Intensity-Modulated Radiotherapy for Lower Gastrointestinal Cancers and the Incidence of Radiation-Induced Lumbosacral Plexopathy,\u201d International Journal of Radiation Oncology*Biology*Physics, vol. 84, no. 2, pp. 376\u2013382, Oct. 2012, doi: 10.1016\/j.ijrobp.2011.11.074.","DOI":"10.1016\/j.ijrobp.2011.11.074"},{"key":"10.1016\/j.radonc.2026.111476_b0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1118\/1.4894702","article-title":"The ANACONDA algorithm for deformable image registration in radiotherapy","volume":"42","author":"Weistrand","year":"2015","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2026.111476_b0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2307\/1932409","article-title":"Measures of the Amount of Ecologic Association between Species","volume":"26","author":"Dice","year":"1945","journal-title":"Ecology"},{"key":"10.1016\/j.radonc.2026.111476_b0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2021.09.010","article-title":"An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation","volume":"164","author":"Slevin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/02841869709109220","article-title":"Specification of the Dose to Organs at risk in External Beam Radiotherapy","volume":"36","author":"Dale","year":"1997","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0065","doi-asserted-by":"crossref","unstructured":"E. Dale, D. R. Olsen, and S. D. Foss\u00c5, \u201cNormal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy,\u201d International Journal of Radiation Oncology*Biology*Physics, vol. 43, no. 2, pp. 385\u2013391, Jan. 1999, doi: 10.1016\/S0360-3016(98)00400-3.","DOI":"10.1016\/S0360-3016(98)00400-3"},{"key":"10.1016\/j.radonc.2026.111476_b0070","doi-asserted-by":"crossref","unstructured":"L. Vaugier et al., \u201cEarly Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07),\u201d Int. J. Radiat. Oncol. Biol. Phys., vol. 103, no. 5, pp. 1061\u20131067, 01 2019, doi: 10.1016\/j.ijrobp.2018.12.020.","DOI":"10.1016\/j.ijrobp.2018.12.020"},{"key":"10.1016\/j.radonc.2026.111476_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109947","article-title":"Re-irradiation in clinical practice: results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform","volume":"189","author":"Willmann","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0080","doi-asserted-by":"crossref","unstructured":"L. A. Van Werkhoven, C. Mattioli, M. T. W. Milder, M. Loi, and J. J. Nuyttens, \u201cUreter Tolerance in Patients Treated with Stereotactic Body Radiation Therapy on Abdominopelvic Lymph Nodes: Analysis on Dose-related Late Toxicity,\u201d International Journal of Radiation Oncology*Biology*Physics, p. S0360301625039070, June 2025, doi: 10.1016\/j.ijrobp.2025.05.087.","DOI":"10.1016\/j.ijrobp.2025.05.087"},{"key":"10.1016\/j.radonc.2026.111476_b0085","doi-asserted-by":"crossref","unstructured":"L. Nenoff et al., \u201cReview and recommendations on deformable image registration uncertainties for radiotherapy applications,\u201d Phys. Med. Biol., vol. 68, no. 24, p. 24TR01, Dec. 2023, doi: 10.1088\/1361-6560\/ad0d8a.","DOI":"10.1088\/1361-6560\/ad0d8a"},{"key":"10.1016\/j.radonc.2026.111476_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110741","article-title":"Radiobiologically equivalent deformable dose mapping for re-irradiation planning: Implementation, robustness, and dosimetric benefits","volume":"205","author":"Garc\u00eda-Alvarez","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110184","article-title":"Multi-centre evaluation of variation in cumulative dose assessment in reirradiation scenarios","volume":"194","author":"Hardcastle","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109527","article-title":"Applicability and usage of dose mapping\/accumulation in radiotherapy","volume":"182","author":"Murr","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111476_b0105","doi-asserted-by":"crossref","unstructured":"E. Vasquez Osorio, C. Mayo, A. Jackson, and A. Appelt, \u201cChallenges of re-irradiation: A call to arms for physicists - and radiotherapy vendors,\u201d Radiotherapy and Oncology, vol. 182, p. 109585, May 2023, doi: 10.1016\/j.radonc.2023.109585.","DOI":"10.1016\/j.radonc.2023.109585"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:06:44Z","timestamp":1789751204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026001155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"alternative-id":["S0167814026001155"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111476","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cumulative dose analysis following elective pelvis re-irradiation at junction with primary prostate radiotherapy from the OLIGOPELVIS GETUG P07 trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111476"}}